Type 2 Diabetes MellitusCDR-MMCNCT03811470
China Diabetes Registry by Metabolic Management Center
An observational study of Type 2 Diabetes Mellitus and Type1 Diabetes Mellitus, run by Guang Ning at 1 site in China.
Trial summary
Epidemiologic studies have revealed a tremendous increase in the prevalence of diabetes and related mortality worldwide. In order to meet all the challenges in the treatment of metabolic diseases in China, the National Metabolic Management Center (MMC) was founded in 2016. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Type 2 Diabetes Mellitus, Type1 Diabetes Mellitus, Monogenetic Diabetes
- What is being tested?
- Standard diabetes management model in each MMC center
- How many people
- 1,000,000 participants
- Where
- 1 siteChina
- Study dates
- 31 May 2017to 31 May 2039
- How long will I take part?
- 20 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: All the patients who are seen and treated at each MMC centers, and meet the In-/Ex-clusion Criteria will be included in this study
Main Inclusion Criteria:
- Age ≥ 18 years old
- Diagnosis of diabetes mellitus based on self-reported history of diagnosed diabetes by clinicians or in line with the current domestic diagnostic criteria for diabetes
- Gender: males and females
- Provide written informed consent
- Satisfactory compliance
Main Exclusion Criteria:
- Patients with significantly reduced life expectancy (less than 5 years)
- With Drug abuse
- With AIDS or syphilis or infectious diseases such as viral hepatitis or tuberculosis in active phase at enrollment
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
National Metabolic Management center
Multiple Locations
Guang Ning, Professor, 8621-64370045 ext. 671817, gning@sibs.ac.cn
Guang Ning, Professor
About this study
Official title: China Diabetes Registry - a Prospective Cohort Study of Patients With Diabetes in National Metabolic Management Centers in China
Epidemiologic studies have revealed a tremendous increase in the prevalence of diabetes and related mortality worldwide. In order to meet all the challenges in the treatment of metabolic diseases in China, the National Metabolic Management Center (MMC) was founded in 2016. The objective of the MMC is to launch a new metabolic disease management model based on the Internet health information platform. It allows the application and evaluation of diabetes treatment strategies at these centers. The proprietary electronic medical database in the MMC will help the dynamic big-data analysis in diabetes epidemiology, prevention, diagnosis, and treatment. It will also provide prospective data support including economic evaluation in management of chronic diseases for the Healthy China 2030 strategy.
Objective
- The purpose of the present study is to establish a multi-center nationwide prospective database of diabetes patients in MMCs, including clinical data, biological samples library so as to explore the epidemiology, genetics, new biomarkers, risk factors, and prognostic methods related to diabetes and its complications, as well as other metabolic diseases.
- To collect cross-sectional data from patients seen and treated at each MMC centers so as to evaluate: the current status of care of patients with diabetes and its related complications, as well as other risk factors treatment strategies at these centers. Patients'costs and quality of life (QoL) will also be evaluated.
- To collect the prospective data of patients treated at each MMC centers in order to evaluate the strategies for the achievement of treatment goals, changes in management, control of risk factors, incidence and progression of all-diabetes related clinical endpoints (including mortality), behavioral changes, psychological well being as well as costs and QoL.
Read the detailed description
Epidemiologic studies have revealed a tremendous increase in the prevalence of diabetes and related mortality worldwide. The general population-based survey in China in 2010, using the American Diabetes Association (ADA) 2010 criteria, revealed that the prevalence of diabetes and prediabetes in adults was 11.6% and 50.1%, respectively, indicating that China has the highest diabetes prevalence in Asia and largest absolute disease burden of diabetes in the world. Lifestyle changes, aging, and obesity have become the main reasons for this increase in the prevalence of diabetes.
In order to meet all the challenges in the treatment of metabolic diseases in China, the National Metabolic Management Center (MMC) was founded in 2016. With advanced medical equipment and Internet of Things (IoT) technology, the MMC is committed to creating an online and offline integrated solution for diabetes, and for the entire spectrum of metabolic disease, to achieve a more convenient and precise model of care for patients. The MMC is focused on establishing highly efficient diagnosis and treatment, as well as comprehensive disease management both in and out of hospital. All MMCs in China have the same structure in terms of facilities, layout, and databases, as well as the same routine daily operations, aiming to establish a platform with standardized diagnosis and treatment of metabolic diseases and their long-term follow-up. This platform of treatment is called the'One Center, One Stop, and One Standard Model'.
The objective of the MMC is to launch a new metabolic disease management model based on the Internet health information platform. It allows the application and evaluation of diabetes treatment strategies at these centers. The proprietary electronic medical database in the MMC will help the dynamic big-data analysis in diabetes epidemiology, prevention, diagnosis, and treatment. It will also provide prospective data support including economic evaluation in management of chronic diseases for the Healthy China 2030 strategy.
Objective：
- The purpose of the present study is to establish a multi-center nationwide prospective database of diabetes patients in MMCs, including clinical data, biological samples library so as to explore the epidemiology, genetics, new biomarkers, risk factors, and prognostic methods related to diabetes and its complications, as well as other metabolic diseases.
- To collect cross-sectional data from patients seen and treated at each MMC centers so as to evaluate: the current status of care of patients with diabetes and its related complications, as well as other risk factors treatment strategies at these centers. Patients'costs and quality of life (QoL) will also be evaluated.
- To collect the prospective data of patients treated at each MMC centers in order to evaluate the strategies for the achievement of treatment goals, changes in management, control of risk factors, incidence and progression of all-diabetes related clinical endpoints (including mortality), behavioral changes, psychological well being as well as costs and QoL.
Methods： After obtaining informed consent, patients will be invited and initiated with a comprehensive baseline evaluation at each MMC centers. Then patients will be followed by clinical/laboratory visits at MMC every 3-6 month later on according to individualized patient's treatment plans. A repeated comprehensive clinical and laboratory assessment for glycemic and risk factors control, safety, as well as diabetes-specific complications will be scheduled once a year.
- Conditions
- Type 2 Diabetes Mellitus, Type1 Diabetes Mellitus, Monogenetic Diabetes, Pancreatogenic Diabetes, Drug-Induced Diabetes Mellitus, Other Forms of Diabetes Mellitus
- Being tested
- Standard diabetes management model in each MMC center
- Medical subject headings
- Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Standard diabetes management model in each MMC centerOther
Standard diabetes management model in each MMC center
| Study group | Role | What they receive |
|---|---|---|
| 1 | Patients with diabetes mellitus including: type 1 or type 2 diabetes mellitus, monogenetic diabetes, pancreatogenic diabetes, drug-induced diabetes, other forms Receives: Other: Standard diabetes management model in each MMC center |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of all diabetes-related clinical endpoints; including: 1. Macrovascular morbidity
Measured: through study completion, up to 20 years
Microvascular morbidity
Measured: through study completion, up to 20 years
Mortality
Measured: through study completion, up to 20 years
Major infections - pulmonary and non-pulmonary requiring hospitalizations
Measured: through study completion, up to 20 years
Heart failure
including hospitalized or treated heart failure, or heart failure death
Measured: through study completion, up to 20 years
Neuropathy
defined as a composite score by the assessment of positive responses among symptoms (by a careful history), sensory signs, or absent or hypoactive reflexes consistent with a distal symmetrical polyneuropathy, and at least one abnormal nerve conduction
Measured: through study completion, up to 20 years
All cancers
The occurrence of any of the following cancers: prostate, breast, lung/bronchus, endometrial, colon, gastric, leukemia, lymphoma, pancreas, kidney/renal pelvis, rectal, and melanoma, etc
Measured: through study completion, up to 20 years
Secondary outcomes (10)
HbA1c (%)
Measured: through study completion, up to 20 years
Fasting and postprandial glucose (mmol/L)
Measured: through study completion, up to 20 years
Blood pressures (mmHg)
Measured: through study completion, up to 20 years
lipids (mg/dl)
Measured: through study completion, up to 20 years
Body mass index (BMI)
Body weight (kg) and height (m) will be combined to report BMI in kg/m^2
Measured: through study completion, up to 20 years
Visceral fat (cm^2)
Measured: through study completion, up to 20 years
Health related quality of life
Evaluated with HQoL scales such as Short Form 12 Health Survey Questionnaire
Measured: through study completion, up to 20 years
Cognitive function
Incidences of all-cause dementia and mild cognitive impairment, cognitive function assessed by cognitive function scale
Measured: through study completion, up to 20 years
Psychological well being
using physiological parameter, questionnaire
Measured: through study completion, up to 20 years
Cost-effectiveness
The incremental cost per quality adjusted life year (QALY) gained. QALYs will be measured by the EuroQol-5 Dimensions (EQ-5D) questionnaire
Measured: through study completion, up to 20 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jan 2019
- Study start31 May 2017
- Primary completion31 May 2037 (estimated)
- Study completion31 May 2039 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for Type 2 Diabetes MellitusStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,000,000 participants (estimated)
- Target duration
- 20 Years
Sponsor and investigators
- Lead sponsor
- Guang Ning
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Guang Ning, Shanghai Jiao Tong University School of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03811470
- Sponsor's protocol ID
- CCEMD-2018-1201
- Acronym
- CDR-MMC
- Status last verified
- Dec 2024
- First submitted
- 20 Dec 2018
- Last updated
- 5 Dec 2024
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Zhang Y, Wang W, Ning G. Metabolic Management Center: An innovation project for the management of metabolic diseases and complications in China. J Diabetes. 2019 Jan;11(1):11-13. doi: 10.1111/1753-0407.12847. Epub 2018 Oct 3. No abstract available.
PubMed 30284373Jiang Y, Gu L, Ma Y, Qu Y, Wan H, Lv K, Zhu Q, Zhou H, Sun J, Lu F, Li X, Wang Y, Zhou J, Liu K, Wang Y, Shen Y. Abnormal Glycaemic Fluctuations Associated With Early Microvascular Changes in the Retina and Choroid of Nondiabetic Adults. Diabetes Obes Metab. 2026 Sep;28(9):7864-7874. doi: 10.1111/dom.70973. Epub 2026 Jun 10.
PubMed 42271560Shi J, Zhao D, Wang J, Wang Y, Dong Q, Hu J, Sha Y, Peng Y, Dai Y, Zheng Q, Xu F, Lan H, Ji B, Li L, Qiu H, Jiang R, Tang R, Qu S, Yang L, Ke T, Li S, Zhao Z, Zhang Y, Wang W; MMC and ChinaMAP Collaborative Group. Sex-specific and BMI-specific associations between visceral fat and diabetic kidney disease in patients with diabetes: a large-scale multicentre prospective cohort study. Lancet Diabetes Endocrinol. 2026 May;14(5):401-411. doi: 10.1016/S2213-8587(26)00001-X.
PubMed 41991218Mu L, Li C, Zhao W, Li A, Zhao D, Zhang B. Association between Sleep Duration and Left Ventricular Hypertrophy for Patients with Type 2 Diabetes Mellitus. Int J Endocrinol. 2023 Nov 28;2023:5532778. doi: 10.1155/2023/5532778. eCollection 2023.
PubMed 38131034Li L, Mi Y, Xu M, Ruan L, Sun J, Song Q. Influence of Dietary Salt Intake on T2D Treatment. Front Endocrinol (Lausanne). 2022 Jun 15;13:926143. doi: 10.3389/fendo.2022.926143. eCollection 2022.
PubMed 35784580Yang X, Lin Y, Xu GD, Chen YS, Zhou Y, Sun J, Li L. Optimal Cut-Off Values of Visceral Fat Area for Predicting Metabolic Syndrome Among Type 2 Diabetes Patients in Ningbo, China. Diabetes Metab Syndr Obes. 2021 Mar 25;14:1375-1383. doi: 10.2147/DMSO.S304164. eCollection 2021.
PubMed 33790605
Study at a glance
From the registry record, last updated by the sponsor on 5 Dec 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- China Diabetes Registry - a Prospective Cohort Study of Patients With Diabetes in National Metabolic Management Centers in China
- ClinicalTrials.gov ID
- NCT03811470
- Acronym / sponsor ID
- CDR-MMC / CCEMD-2018-1201
- Conditions
- Type 2 Diabetes Mellitus, Type1 Diabetes Mellitus, Monogenetic Diabetes, Pancreatogenic Diabetes, Drug-Induced Diabetes Mellitus, Other Forms of Diabetes Mellitus
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 1,000,000 participants (estimated)
- Lead sponsor
- Guang NingUniversity, hospital or other
- Study start
- 31 May 2017 (actual)
- Primary completion
- 31 May 2037 (estimated)
- Study completion
- 31 May 2039 (estimated)
- First posted
- 22 Jan 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Epidemiologic studies have revealed a tremendous increase in the prevalence of diabetes and related mortality worldwide. In order to meet all the challenges in the treatment of metabolic diseases in China, the National Metabolic Management Center (MMC) was founded in 2016. The objective of the MMC is to launch a new metabolic disease management model based on the Internet health information platform. It allows the application and evaluation of diabetes treatment strategies at these centers. The proprietary electronic medical database in the MMC will help the dynamic big-data analysis in diabetes epidemiology, prevention, diagnosis, and treatment. It will also provide prospective data support including economic evaluation in management of chronic diseases for the Healthy China 2030 strategy.
Objective
- The purpose of the present study is to establish a multi-center nationwide prospective database of diabetes patients in MMCs, including clinical data, biological samples library so as to explore the epidemiology, genetics, new biomarkers, risk factors, and prognostic methods related to diabetes and its complications, as well as other metabolic diseases.
- To collect cross-sectional data from patients seen and treated at each MMC centers so as to evaluate: the current status of care of patients with diabetes and its related complications, as well as other risk factors treatment strategies at these centers. Patients'costs and quality of life (QoL) will also be evaluated.
- To collect the prospective data of patients treated at each MMC centers in order to evaluate the strategies for the achievement of treatment goals, changes in management, control of risk factors, incidence and progression of all-diabetes related clinical endpoints (including mortality), behavioral changes, psychological well being as well as costs and QoL.
Detailed description
Epidemiologic studies have revealed a tremendous increase in the prevalence of diabetes and related mortality worldwide. The general population-based survey in China in 2010, using the American Diabetes Association (ADA) 2010 criteria, revealed that the prevalence of diabetes and prediabetes in adults was 11.6% and 50.1%, respectively, indicating that China has the highest diabetes prevalence in Asia and largest absolute disease burden of diabetes in the world. Lifestyle changes, aging, and obesity have become the main reasons for this increase in the prevalence of diabetes.
In order to meet all the challenges in the treatment of metabolic diseases in China, the National Metabolic Management Center (MMC) was founded in 2016. With advanced medical equipment and Internet of Things (IoT) technology, the MMC is committed to creating an online and offline integrated solution for diabetes, and for the entire spectrum of metabolic disease, to achieve a more convenient and precise model of care for patients. The MMC is focused on establishing highly efficient diagnosis and treatment, as well as comprehensive disease management both in and out of hospital. All MMCs in China have the same structure in terms of facilities, layout, and databases, as well as the same routine daily operations, aiming to establish a platform with standardized diagnosis and treatment of metabolic diseases and their long-term follow-up. This platform of treatment is called the'One Center, One Stop, and One Standard Model'.
The objective of the MMC is to launch a new metabolic disease management model based on the Internet health information platform. It allows the application and evaluation of diabetes treatment strategies at these centers. The proprietary electronic medical database in the MMC will help the dynamic big-data analysis in diabetes epidemiology, prevention, diagnosis, and treatment. It will also provide prospective data support including economic evaluation in management of chronic diseases for the Healthy China 2030 strategy.
Objective：
- The purpose of the present study is to establish a multi-center nationwide prospective database of diabetes patients in MMCs, including clinical data, biological samples library so as to explore the epidemiology, genetics, new biomarkers, risk factors, and prognostic methods related to diabetes and its complications, as well as other metabolic diseases.
- To collect cross-sectional data from patients seen and treated at each MMC centers so as to evaluate: the current status of care of patients with diabetes and its related complications, as well as other risk factors treatment strategies at these centers. Patients'costs and quality of life (QoL) will also be evaluated.
- To collect the prospective data of patients treated at each MMC centers in order to evaluate the strategies for the achievement of treatment goals, changes in management, control of risk factors, incidence and progression of all-diabetes related clinical endpoints (including mortality), behavioral changes, psychological well being as well as costs and QoL.
Methods： After obtaining informed consent, patients will be invited and initiated with a comprehensive baseline evaluation at each MMC centers. Then patients will be followed by clinical/laboratory visits at MMC every 3-6 month later on according to individualized patient's treatment plans. A repeated comprehensive clinical and laboratory assessment for glycemic and risk factors control, safety, as well as diabetes-specific complications will be scheduled once a year.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 20 Years
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| 1 | – | Other: Standard diabetes management model in each MMC centerPatients with diabetes mellitus including: type 1 or type 2 diabetes mellitus, monogenetic diabetes, pancreatogenic diabetes, drug-induced diabetes, other forms |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- All the patients who are seen and treated at each MMC centers, and meet the In-/Ex-clusion Criteria will be included in this study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Standard diabetes management model in each MMC centerStandard diabetes management model in each MMC center | Other | 1 |
Primary outcome
Incidence of all diabetes-related clinical endpoints; including: 1. Macrovascular morbidity
Time frame: through study completion, up to 20 years
Microvascular morbidity
Time frame: through study completion, up to 20 years
Mortality
Time frame: through study completion, up to 20 years
Major infections - pulmonary and non-pulmonary requiring hospitalizations
Time frame: through study completion, up to 20 years
Heart failure
Time frame: through study completion, up to 20 years
including hospitalized or treated heart failure, or heart failure death
Neuropathy
Time frame: through study completion, up to 20 years
defined as a composite score by the assessment of positive responses among symptoms (by a careful history), sensory signs, or absent or hypoactive reflexes consistent with a distal symmetrical polyneuropathy, and at least one abnormal nerve conduction
All cancers
Time frame: through study completion, up to 20 years
The occurrence of any of the following cancers: prostate, breast, lung/bronchus, endometrial, colon, gastric, leukemia, lymphoma, pancreas, kidney/renal pelvis, rectal, and melanoma, etc
10 secondary outcomes
HbA1c (%)
Time frame: through study completion, up to 20 years
Fasting and postprandial glucose (mmol/L)
Time frame: through study completion, up to 20 years
Blood pressures (mmHg)
Time frame: through study completion, up to 20 years
lipids (mg/dl)
Time frame: through study completion, up to 20 years
Body mass index (BMI)
Time frame: through study completion, up to 20 years
Visceral fat (cm^2)
Time frame: through study completion, up to 20 years
Health related quality of life
Time frame: through study completion, up to 20 years
Cognitive function
Time frame: through study completion, up to 20 years
Psychological well being
Time frame: through study completion, up to 20 years
Cost-effectiveness
Time frame: through study completion, up to 20 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Dec 2024.
- Background: PubMed 30284373Zhang Y, Wang W, Ning G. Metabolic Management Center: An innovation project for the management of metabolic diseases and complications in China. J Diabetes. 2019 Jan;11(1):11-13. doi: 10.1111/1753-0407.12847. Epub 2018 Oct 3. No abstract available.
- Derived from this study: PubMed 42271560Jiang Y, Gu L, Ma Y, Qu Y, Wan H, Lv K, Zhu Q, Zhou H, Sun J, Lu F, Li X, Wang Y, Zhou J, Liu K, Wang Y, Shen Y. Abnormal Glycaemic Fluctuations Associated With Early Microvascular Changes in the Retina and Choroid of Nondiabetic Adults. Diabetes Obes Metab. 2026 Sep;28(9):7864-7874. doi: 10.1111/dom.70973. Epub 2026 Jun 10.
- Derived from this study: PubMed 41991218Shi J, Zhao D, Wang J, Wang Y, Dong Q, Hu J, Sha Y, Peng Y, Dai Y, Zheng Q, Xu F, Lan H, Ji B, Li L, Qiu H, Jiang R, Tang R, Qu S, Yang L, Ke T, Li S, Zhao Z, Zhang Y, Wang W; MMC and ChinaMAP Collaborative Group. Sex-specific and BMI-specific associations between visceral fat and diabetic kidney disease in patients with diabetes: a large-scale multicentre prospective cohort study. Lancet Diabetes Endocrinol. 2026 May;14(5):401-411. doi: 10.1016/S2213-8587(26)00001-X.
- Derived from this study: PubMed 38131034Mu L, Li C, Zhao W, Li A, Zhao D, Zhang B. Association between Sleep Duration and Left Ventricular Hypertrophy for Patients with Type 2 Diabetes Mellitus. Int J Endocrinol. 2023 Nov 28;2023:5532778. doi: 10.1155/2023/5532778. eCollection 2023.
- Derived from this study: PubMed 35784580Li L, Mi Y, Xu M, Ruan L, Sun J, Song Q. Influence of Dietary Salt Intake on T2D Treatment. Front Endocrinol (Lausanne). 2022 Jun 15;13:926143. doi: 10.3389/fendo.2022.926143. eCollection 2022.
- Derived from this study: PubMed 33790605Yang X, Lin Y, Xu GD, Chen YS, Zhou Y, Sun J, Li L. Optimal Cut-Off Values of Visceral Fat Area for Predicting Metabolic Syndrome Among Type 2 Diabetes Patients in Ningbo, China. Diabetes Metab Syndr Obes. 2021 Mar 25;14:1375-1383. doi: 10.2147/DMSO.S304164. eCollection 2021.
- Individual participant dataSharing planned: Undecided
Related trials for Type 2 Diabetes Mellitus
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Type 2 Diabetes Mellitus and Type1 Diabetes Mellitus, run by Guang Ning at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 5 Dec 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Guang Ning, MD,PHD (008621-64370045 ext. 671817, gning@sibs.ac.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of all diabetes-related clinical endpoints; including: 1. Macrovascular morbidity (time frame: through study completion, up to 20 years). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03811470, which also lists 6 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Dec 2024.